
Join to View Full Profile
2121 Kenny Rd FL 5Columbus, OH 43221
Phone+1 614-293-6196
Dr. Meng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lingbin Meng, MD, PhD, is a distinguished medical oncologist at The Ohio State University Comprehensive Cancer Center - James (OSUCCC – James), specializing in genitourinary cancers, including those of the prostate, bladder, kidney, and testicles. Following a hematology/oncology fellowship at the H. Lee Moffitt Cancer Center & Research Institute, Dr. Meng has dedicated her career to advancing both patient care and clinical research. She places a strong emphasis on personalized treatment plans that reflect each patient's unique needs, values, and preferences, incorporating advanced therapies and opportunities to participate in pioneering clinical trials. As a member of the Translational Therapeutics Program at The James, Dr. Meng actively contributes to the field with over 70 scholarly articles in top-tier journals and has received multiple accolades, such as the Conquer Cancer Merit Award from the American Society of Clinical Oncology. In addition to her clinical practice, Dr. Meng serves as an assistant professor and is involved in training the next generation of physicians, underscoring her commitment to improving cancer care through impactful research and education.
Education & Training
- University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2020 - 2023
- AdventHealth Florida (Orlando)Residency, Internal Medicine, 2017 - 2020
- University of louisville PhD, Anatomical Science and Biology, 2009 - 2014
- Peking Union Medical CollegeMater, Plastic Surgery, 2008 - 2009
- Anhui Medical UniversityClass of 2008
Certifications & Licensure
- OH State Medical License 2023 - 2027
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Awards Chinese American Hematologist and Oncologist Network, 2022
- ASCO Conquer Cancer Merit Award American Society of Clinical Oncology Annual Conference, 2022
- Research Poster Winner of ACP Internal Medicine National Conference American College of Physicians, 2019
- Join now to see all
Clinical Trials
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Start of enrollment: 2023 Dec 11
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Start of enrollment: 2024 Feb 02
Publications & Presentations
PubMed
- CNPY2 drives DSS-induced colitis via the macrophage-ROS axis.Wenqing Zhang, Lingbin Meng, Xiaoli Zhang, Zihai Li, Feng Hong
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025-04-21 - A novel TLR4 accessory molecule drives hepatic oncogenesis through tumor-associated macrophages.Doyeon Kim, Carter A Allen, Dongjun Chung, Lingbin Meng, Xiaoli Zhang
Cancer Letters. 2025-04-01 - CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications.Sayan Mullick Chowdhury, Feng Hong, Christian Rolfo, Zihai Li, Kai He
Biology. 2025-02-18
Press Mentions
- Upfront TKI for Bone-Predominant RCC Tops Single-Agent ImmunotherapyNovember 12th, 2024
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: